Wuhan YZY Biopharma

Company snapshot

Wuhan YZY Biopharma Co. Ltd. YZY Biopharma is a biotech company whose vision is to develop new class of innovative medicines based on breakthrough discovery in molecular biology. The company was founded in July 0f 2010, and is located in Wuhan National Biological Industry Base – Wuhan Biolake. As our scientists continue to investigate molecular disease targets to impact a broad range of human canc

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Wuhan YZY Biopharma. Not investment advice.

• What is Wuhan YZY Biopharma?

  Wuhan YZY Biopharma is a biotech organization headquartered in CN. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalT

• Is Wuhan YZY Biopharma publicly traded?

  Wuhan YZY Biopharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Wuhan YZY Biopharma develop or market?

  We link 2 drug profile(s) where Wuhan YZY Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/wuhan-yzy-biopharma-co#company-drugs.

• What are the latest developments for Wuhan YZY Biopharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Wuhan YZY Biopharma focus on?

  Wuhan YZY Biopharma focuses on Relapsed or Refractory Multiple Myeloma based on our analysis of their pipeline programs and drug development activities.